Cellectis S.A. (CLLS) News
Filter CLLS News Items
CLLS News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
CLLS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CLLS News From Around the Web
Below are the latest news stories about CELLECTIS SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.
Monthly information on share capital and company voting rights(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of votingrights12/31/2024100,093,87388,660,539 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, [email protected] Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 |
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't?Investors need to pay close attention to Cellectis (CLLS) stock based on the movements in the options market lately. |
Analysts Predict 400% Upside Potential for This Penny StockWith cancer therapies and TALEN-based gene editing, Cellectis is projected to hit an average target price of $7.00, offering massive upside potential |
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million (“Tranche C”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). With the dr |
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual MeetingNEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC), that will take place on November 6-10, 2 |
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as o |
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday, Nov |
Cellectis Presents New Gene-Editing BreakthroughsCellectis SA (CLLS) has released an update. Cellectis SA is set to present groundbreaking data on their gene-editing technologies at the ESGCT Annual Congress, showcasing advancements in TALE base editors and non-viral gene insertion methods. These developments could significantly enhance therapeutic applications, offering promising new avenues for gene therapy in hematopoietic stem and progenitor cells. Investors may find these innovations indicative of Cellectis’ potential for influencing futu |
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual CongressNEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be showcasing pre-clinical data that permit the design of an efficient and specific TALE base editors (TALEB) as well as a process to enhance the efficacy of non-viral gene insertion in hematopoietic stem and progenitor cells (H |
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?CERVOMED INC (CRVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |